Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Bristol-Myers Squibb 1Q11 | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Bristol-Myers Squibb 1Q11

U.S. sales were up 5% to $3.3 billion in the quarter.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Bristol-Myers Squibb 1Q11

1Q Revenues: $5.0 billion (+4%)

1Q Earnings: $986 million (+33%)

Comments: U.S. sales were up 5% to $3.3 billion in the quarter. International sales increased 3% to $1.8 billion (1% excluding foreign exchange impact). Plavix sales were up 6% to $1.8 billion. Sustiva Franchise sales were $343 million (+2%). Baraclude sales were $275 million (+27%). Sprycel sales were up 31% to $172 million. Orencia sales were up 18% to $199 million. Abilify sales were $624 million (+1%). Reyataz sales were $366 million (-2%). R&D expenses increased 3% to $935 million in the quarter.


Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters